skip to content
  1. Home
  2. >
  3. Investment Q&A
You can view 3 more answers this month. Sign up for a free trial for unlimited access.

Investment Q&A

Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.

Q: Hi Team, apples to oranges but I bought GILD a while back for growth. What would you consider if deciding to switch to CRH Medical. Size, geography, I know. But for a five year growth play does this make any sense from a risk return perspective? Thank you, Michael
Read Answer Asked by Michael on February 16, 2017
Q: Can you please comment or provide any opinion on ATE phase2 trials for their ATB-346 drug? my understanding is that results of liver tests in test patients have provided mixed results from the trials. Also please provide forecast for share price going forward based on potential drug trial success? I know they have been obtaining private funds and i believe GUD has 10 or 20% stake in ATE. thanks
Read Answer Asked by Gordon on February 13, 2017
Q: For a TFSA. any one of these preferable

Choosing only GUD a sound choice, if one wanted maximum result
Read Answer Asked by Serge on February 13, 2017
Q: Hello, I would like to purchase has some more of these shares but am worried about the potential of the USA cross border tax and especially in the health care field. Do you believe CRH would be included in this tax and should I hold off and see what happens and how will I be able to tell when or if the tax will be imposed? Thanks for your insight.

Read Answer Asked by rick on February 10, 2017
Q: Hi ,if you can clarify a scenario
- Using the finaning done by CVM.v as an example . They raised $12 million at .33 with a 1/2 warrant (full warrant exercise price .70 for 18 months)
The share price was at around .45 yesterday and gapped up to the .55 area today
What are the most likley reasons the share price goes up on this news?
Is it possible they drive it up to short (covering with their .33 cent shares) or is it just a positive reaction to funding
Thanks and excuse any ignorance
David
Read Answer Asked by David on February 08, 2017
Q: I realize that I have a poor understanding of how to value "pre-sales" biotech companies such as TR. How is a quantitative value placed on them - I assume it is based somehow on the potential market share of the company in the specific area they are developing drugs for, as well as the size of that market and the risk of getting product to commercial trade. But this seems all very subjective. For example, TRIL has traded all over the map, the value can seem to double or be cut in half based on some combination of risk profile vs. potential. For the average retail investor, how does one go about trying to value these companies, or is is better to wait until sales start to happen and then try to value to company on sales projection? Other examples could be PLI, or one I'm still trying to forget from years past, ISA. I'm wondering if these types of companies have a place in a responsible portfolio even one is "high growth" oriented?
Read Answer Asked by Kel on February 06, 2017
Looking for more? Sign up for a FREE 14 day trial! No credit card required

We invite you to sign up for a 14 day free trial of 5i Research!
Experience all the benefits and tools we have to offer; stock research, model portfolios, Q&A with our experts, and so much more. Join a community of like-minded investors today!